Quinlan Sievers

7PUBLICATIONS
114CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 22, 2026
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.

|Apr 30, 2026
Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

|Feb 01, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.

Skye Montoya, Jessie Bourcier, Mark Noviski

|Jan 07, 2021
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.

Max Jan, Irene Scarfò, Rebecca C Larson

|May 03, 2019
Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Adam S Sperling, Michael Burgess, Hasmik Keshishian

|Nov 03, 2018
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.

Quinlan L Sievers, Georg Petzold, Richard D Bunker

Pageof 2

Frequent Collaborators

3 joint publications

Omar Abdel-Wahab

2 joint publications

Ying Siow May Tan

2 joint publications

Stefan Gajewski

2 joint publications

Ratul Mukerji